CA05 Lead Identification

Jul 21, 2022 | ROAD MAP 2022, SCIENCE

CA05 - Lead Identification

We have identified insilico, several compounds as inhibitors of CA05, which is a protein kinase overexpressed in various types of tumors with a clear oncogenic role and no type-specific inhibitor, and we have started in vitro trials to select a lead.

CA02/03 Target Identification vs NSCLC

Jan 21, 2022 | ROAD MAP 2022, SCIENCE

CA02/03 - Target Identification

CancerAppy has identified two membrane proteins that are upregulated in NSCLC and has patented their use as targets to vectorize compounds against these tumors, or as surrogates for immune activation, to select patients o explore combinations with new immune therapies